The researcher at the University of Greifswald (Germany) who identified the cause of thrombosis in those vaccinated with AstraZeneca , Andreas Greinacher, assures that young women are not more at risk of these adverse effects.
AstraZeneca thrombosis is not a disease of young women
Most thromboembolic events arising in AstraZeneca vaccinates have been recorded in young women. Thus, some European countries, such as Spain, made the decision to only administer the Oxford serum in those over 60 years of age to maximize the benefits with respect to the risk. In the same way, the Ministry of Health made the decision to administer the Janssen vaccine , which also produces blood clots, only in those older than 70 years.
These decisions, however, have not followed scientific criteria, since the European Medicines Agency (EMA) did not find risk factors in cases of thrombosis. In the same way, the scientist Andreas Greinacher, asked by the SINC agency , explains that he is "increasingly skeptical" about the correlation between cases of thrombosis with sex and age.
"In Germany it occurs in young women because 73% of health workers are," explained the scientist. "The information I have from Canada is that they begin to see it in men and women alike, and in the United Kingdom it is quite balanced although it tends towards women. It is not a disease of young women," he said. However, the expert commented that women are somewhat more likely to develop an autoimmune response, which is the trigger for clotting.
